Alimera Sciences Announces Late Breaking Presentation Of New ILUVIEN Analysis During Retina Subspecialty Day At American Academy of Ophthalmology Annual Meeting 2015
ATLANTA, Nov. 4, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that a 36-month analysis of patients treated with ILUVIEN® has been accepted as a Late Breaking Development during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting 2015. The presentation, "Analysis of Diabetic Retinopathy Progression in Patients Treated with 0.2 microns/day Fluocinolone Acetonide Over 36 Months" by Charles C. Wykoff, M.D., Ph.D., Retina Consultants of Houston, is slated for November 14 at 9:21 a.m. at the Sands Expo/Venetian, Las Vegas.
The 2015 Retina Subspecialty Day provides a comprehensive and focused medical and surgical retina update for retina subspecialists, interested ophthalmologists, and ophthalmologists in training. The meeting focuses on up-to-date, clinically and scientifically relevant topics presented by an international group of respected retina specialists.
"We are very pleased the AAO scientific reviewers selected this analysis for presentation as a Late Breaking Development," said Dan Myers, Alimera president and chief executive officer.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alimera-sciences-announces-late-breaking-presentation-of-new-iluvien-analysis-during-retina-subspecialty-day-at-aao-annual-meeting-2015-300170110.html
SOURCE Alimera Sciences, Inc.